NCT05187338View on ClinicalTrials.gov

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

October 30, 2029

Study Completion Date

October 30, 2035

Conditions
Lung CancerLiver CancerColorectal CancerPancreas CancerOvary CancerHead and Neck CancerBreast CancerGastric CancerCervical CancerEsophageal CancerSarcoma
Interventions
DRUG

ipilimumab +pembrolizumab +durvalumab

"This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."

Trial Locations (1)

510260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER